Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Niraparib Plus Bevacizumab Shows Promise in High-Risk Ovarian Cancer Population

March 19th 2022

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.

Intravenous Chemo/Bevacizumab Shows Comparable Survival Outcomes Vs Intraperitoneal Regimen in Advanced Ovarian Cancer

March 19th 2022

Intravenous chemotherapy plus bevacizumab did not demonstrate differences in progression-free and overall survival compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease.

Olaparib Shows Comparable OS to Chemotherapy in BRCA+, Platinum-Sensitive, Relapsed Ovarian Cancer

March 19th 2022

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical Cancer

March 19th 2022

Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical Cancer

March 19th 2022

Mae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.

Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma

March 19th 2022

Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma

A Variety of Clinical and Molecular Factors Mark Long-Term PFS in PSR OC Treated with Olaparib

March 18th 2022

Patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation treated with maintenance olaparib who achieved long-term progression-free survival more often had homologous recombination deficiency-positive tumors compared with those who experienced a short-term PFS.

Olaparib Maintenance After Response to First-Line Chemo Under Exploration in BRCA Wild-Type Advanced Ovarian Cancer

March 18th 2022

Maintenance therapy with olaparib will be examined in patients with BRCA1/2 wild-type advanced ovarian cancer who responded to first-line, platinum-based chemotherapy in the phase 3 MONO-OLA1 trial.

Phase 3 Trial Seeks to Confirm Oregovomab Benefit in Advanced Ovarian Cancer

March 18th 2022

Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial.

Ociperlimab/Tislelizumab Combo Under Exploration in Previously Treated Recurrent or Metastatic Cervical Cancer

March 18th 2022

The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer.

Antolitinic/Sintilimab Combination Under Investigation for OCCC in China

March 18th 2022

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

Investigators Assess Benefit of Adjuvant Pembrolizumab Plus Chemotherapy Combinations in High-Risk Endometrial Cancer

March 18th 2022

The durable antitumor activity of pembrolizumab and the clinically beneficial outcomes demonstrated with both adjuvant chemotherapy and adjuvant chemoradiotherapy have provided investigators with the foundation to assess the 2 approaches in combination in a phase 3 study.

I/O + Chemotherapy Treatments for Endometrial Carcinoma

March 18th 2022

A review of data from several clinical trials on the use of I/O + chemotherapy as treatment for endometrial carcinoma.

Endometrial Carcinoma: Clinical Case Scenario 2

March 18th 2022

Experts explain the need for germline testing and genetic counseling for patients with endometrial carcinoma as demonstrated by a patient case.

Selinexor Maintenance Improves PFS in Advanced or Recurrent Endometrial Cancer, Particularly p53 Wild-Type Subset

March 18th 2022

Selinexor reduced the risk of disease progression or death by 30% in an audited intent-to-treat population of patients with advanced or recurrent endometrial cancer who received frontline chemotherapy, and by 62% in a subset of patients with p53 wild-type disease, according to data from the phase 3 SIENDO trial.

Molecular Testing in Endometrial Cancer

March 15th 2022

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Endometrial Cancer: A Global Problem

March 15th 2022

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Dr. Olawaiye on the Social and Biological Determinants of Disparities in Women’s Cancer

March 12th 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Sintilimab/Anlotinib Produces Meaningful Responses in PD-L1+ Recurrent or Metastatic Cervical Cancer

March 11th 2022

The addition of anlotinib to sintilimab appeared to be efficacious and safe when used as a second- or later-line treatment in patients with PD-L1–positive, recurrent or metastatic cervical cancer.

Dose Reduction in Endometrial Carcinoma Treatment

March 10th 2022

Drs Bradley Monk and David O’Malley explain dose reduction in endometrial carcinoma treatment based on clinical trial data.